Alexander I. Spira, MD, PhD, FACP, discusses the next steps in the clinical development of zoldonrasib for patients with KRAS ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

The LumiSystem is a detection tool that uses fluorescence imaging technology during lumpectomy, offering a more complete resection vs other detection systems that evaluate tissue after surgical ...

The use of radiation therapy has become a staple in breast cancer treatment, with benefits seen in node-positive patients, those with locally advanced disease, and those with large-sized tumors.

Evan Y. Yu, MD, discusses the design and objectives of the phase 3 PEACE 3 study, which evaluates the combination of enzalutamide (ENZA) and radium-223 (Ra-223) in androgen receptor pathway inhibitor ...

Evan Y. Yu, MD, discusses the therapeutic options for metastatic castration-resistant prostate cancer (mCRPC) included in the National Comprehensive Cancer Network (NCCN) guidelines, such as ...

During a Case-Based Roundtable® event, Thach-Giao Truong, MD, discussed how data from the CheckMate-067 and RELATIVITY-047 ...

Pathologists supported by a new artificial intelligence tool outperformed Standard of Care/Gold standard in determining ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

In a live event, Vinay Minocha, MD, discusses the addition of darolutamide to androgen deprivation therapy for in patients ...

Alec Kimmelman, MD, PhD, and Shridar Ganesan, MD, PhD, discuss the institution's new molecular oncology program.